Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Patients With HER2 Mutant Metastatic Non-small Cell Lung Cancer: a Prospective, Observational Study (RERUN)

NCT06809764 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT06809764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06809764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Patients With HER2 Mutant Metastatic Non-small Cell Lung Cancer: a Prospective, Observational Study (RERUN)
Lead sponsor
Daiichi Sankyo
Phase
Observational
Overall status
Recruiting
Start date
February 21, 2025
Completion date
February 12, 2027
Enrollment
150 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer